Candel Therapeutics, Inc. CADL Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s change in accrued liabilities?
- Candel Therapeutics, Inc. (CADL) reported change in accrued liabilities of -$3.86M in Q1 2026.
- How has Candel Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Candel Therapeutics, Inc.'s change in accrued liabilities decreased by 62.9% year-over-year, from -$2.37M to -$3.86M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.